View the Latest: Prescription Drugs
Filter
-
-
2014 Employer Health Benefits Survey
FeatureThis annual Employer Health Benefits Survey (EHBS) provides a detailed look at trends in employer-sponsored health coverage, including premiums, employee contributions, cost-sharing provisions, and other relevant information. The 2014 EHBS survey finds average family health premiums rose 3 percent in 2014, relatively modest growth by historical standards.
-
Medicare Part D in Its Ninth Year: The 2014 Marketplace and Key Trends, 2006-2014
ReportThis report presents findings from an analysis of the Medicare Part D marketplace in 2014 and changes in features of the drug benefit offered by Part D plans since 2006. It examines the latest information and trends related to Part D enrollment and plan availability, premiums, benefit design and cost sharing, pharmacy networks, the Low-Income Subsidy Program, and plan performance ratings.
-
How Does Prescription Drug Spending and Use Compare Across Large Employer Plans, Medicare Part D, and Medicaid?
Issue BriefPrescription drug costs are a pressing concern for both consumers and policymakers. This analysis compares prescription drug spending and use in large private employer plans, Medicare Part D, and Medicaid, based primarily on claims data by payer, which does not account for rebates.
-
Medicaid’s Prescription Drug Benefit: Key Facts
Fact SheetMedicaid provides health coverage for millions of Americans, including prescription drug coverage for many people with substantial health needs. This fact sheet provides an overview of Medicaid’s prescription drug benefit and recent trends in spending and utilization
-
Potential Implications of Policy Changes in Medicaid Drug Purchasing
Issue BriefThis brief examines how leading federal and state policy options related to changes in Medicaid Drug Rebate Program (MDRP), drug pricing, and payment and management of the Medicaid prescription drug would affect state and federal governments as well as private industry (including drug manufacturers, managed care organizations, and pharmacies).
-
Moving the Needle on Prescription Drug Costs: Using the Innovation Center and Other Demonstration Authority
Issue BriefThis brief examines how the CMS Innovation Center (also known as CMMI) and Section 402 demonstration authority could become pathways for the Biden Administration to implement policy changes related to prescription drug costs.
-
Strategies To Lower Drug Costs Top the Public’s Health Priorities for Congress
News ReleaseAgainst the backdrop of public concern about inflation and rising gas prices, proposals to lower what people pay out-of-pocket for drugs tops the public’s list of health care priorities for Congress, a new KFF Health Tracking Poll finds. Most (55%) of the public say inflation is the biggest problem facing the country.
-
How Medicare’s New Drug Price Negotiation Program Could Expand Access to Selected Drugs
Issue BriefThis brief examines how Part D enrollees’ access to and utilization of the first set of 10 selected drugs could be affected by the new Part D coverage and formulary requirements for selected drugs established by the Inflation Reduction Act and in CMS guidance, as well as the potential for lower out-of-pocket costs.
-
KFF Tracking Poll July 2023: Substance Use Crisis And Accessing Treatment
Poll FindingIn the midst of an opioid epidemic in the United States, two-thirds of adults say either they or a family member have been impacted by drug or alcohol addiction. Three in ten say they or their family were addicted to prescription or illegal opioids. This survey explores treatments received by those who battled addiction, impacts of addiction, and support for policies aimed at reducing drug overdoses.